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Abstract
Myotonia congenita (MC) is a skeletal-muscle hyperexcitability disorder caused by loss-of-
function mutations in the ClC-1 chloride channel. Mutations are scattered over the entire
sequence of the channel protein, withmore than 30mutations located in the poorly characterized
cytosolic C-terminal domain. In this study, we characterized, through patch clamp, seven ClC-1
mutations identified in patients affected byMCof various severities and located in the C-terminal
region. The p.Val829Met, p.Thr832Ile, p.Val851Met, p.Gly859Val, and p.Leu861Pro mutations
reside in the CBS2 domain, while p.Pro883Thr and p.Val947Glu are in the C-terminal peptide.
We showed that the functional properties of mutant channels correlated with the clinical pheno-
types of affected individuals. In addition, we defined clusters of ClC-1mutations within CBS2 and
C-terminal peptide subdomains that share the same functional defect: mutations between 829
and 835 residues and in residue 883 induced an alteration of voltage dependence, mutations
between 851 and 859 residues, and in residue 947 induced a reduction of chloride currents,
whereas mutations on 861 residue showed no obvious change in ClC-1 function. This study
improves our understanding of the mechanisms underlying MC, sheds light on the role of the
C-terminal region inClC-1 function, and provides information to develop newantimyotonic drugs.
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1 INTRODUCTION
Myotonia congenita (MC) (MIM# 160800) belongs to the group of
nondystrophic myotonias and can be inherited either in an autosomal
dominant (Thomsen disease) or a recessive manner (Becker disease).
Clinically, this disorder is characterized bymyotonic discharges at elec-
tromyography and delayed muscle relaxation (stiffness), sometimes
accompanied by muscle hypertrophy, transient weakness, cramping,
and/or pain (Imbrici et al., 2015a; Lehmann-Horn, Jurkat-Rott, &
Rüdel, 2008; Tang & Chen, 2011). The symptoms are mitigated by
mexiletine, a sodium channel blocker that represents the first-choice
therapeutic option for MC (Imbrici et al., 2016a; Lo Monaco, D'Amico,
Luigetti, Desaphy, & Modoni, 2015; Statland et al., 2012; Suetterlin
et al., 2015). MC is caused by loss-of-function mutations in the CLCN1
gene (MIM# 118425), encoding the major skeletal-muscle chloride
channel ClC-1. The majority of MC mutations reduce membrane
surface channel expression due to defective trafficking or cause
changes of channel function including shifts of voltage dependence of
protopore and common gating, reduced single channel conductance,
or altered ion selectivity (Desaphy et al., 2013; Fahlke, Beck, &George,
1997; Imbrici et al., 2015a; Pusch, Steinmeyer, Koch, & Jentsch, 1995;
Ronstedt et al., 2015; Ulzi et al., 2012; Vindas-Smith et al., 2016;
Warnstedt et al., 2002; Weinberger et al., 2012; Wu et al., 2002). This
channel is a homodimer, composed of two identical subunits, each
forming a gated pore. Each subunit consists of 18 𝛼-helices (helices
A to R), 17 of which are embedded in the plasma membrane and
2 tandem cystathionine-𝛽-synthase (CBS) domains are located in the
intracellular C-terminal region (Markovic & Dutzler, 2007; Meyer &
Dutzler, 2006; Park & MacKinnon, 2018). The ClC-1 channels are the
major contributors to the resting membrane conductance, which is
crucial for the correct membrane repolarization and propagation of
action potential (Imbrici et al., 2015a; Nielsen, De Paoli, Riisager, &
Pedersen, 2017). The myotonic mutations identified up to date are
widely distributed across the entire sequence of the channel protein,
both in the transmembrane region and in the cytosolic N-terminal
and C-terminal parts. The C-terminal cytoplasmic region, including
the two CBS domains, is notably large. It contains about 400 of the
991 amino acid residues forming the ClC-1 monomer (Estévez, Pusch,
Ferrer-Costa, Orozzo, & Jentsch, 2004; Hebeisen et al., 2004). Various
functional roles have been proposed for this region, such as regulation
of ClC-1 trafficking and gating, modulation by intracellular ATP,
NAD+, and PKC and sensitivity to external chloride (Bennetts et al.,
2005; Bennetts, Yu, Chen, & Parker, 2012; Hebeisen & Fahlke, 2005;
Hsiao, Huang, Tang, & Lin, 2010). However, the precise physiological
significance remains to be elucidated. Experiments performed in the
myotonic goat identified a single-nucleotide mutation in ClC-1 CBS2
(corresponding toA885P in humanClC-1),which causes the symptoms
of myotonia and reduces chloride conductance due to the shift of the
channel open probability to more positive potentials (Beck, Fahlke,
& George, 1996). Since then, at least 14 missense and 20 nonsense
mutations have been found in the C-tail of ClC-1 (Leiden Database):
some of these variants have been identified as polymorphisms
(e.g., p.Pro727Leu), whereas others were functionally characterized
and associated with dominant or recessive myotonic phenotypes
(Brugnoni et al., 2013; Fialho et al., 2007; Liu et al., 2015; Macias et al.,
2007).
Here, we provide the functional characterization of seven mis-
sense mutations identified in myotonic patients and located in the
CBS2 domain (p.Val829Met, p.Thr832Ile, p.Val851Met, p.Gly859Val,
and p.Leu861Pro) and C-peptide (p.Pro883Thr and p.Val947Glu) of
hClC-1, with the aim of verifying mutation pathogenicity and to gain
insight into the role of the C-terminal in ClC-1 function. We found
that ClC-1 mutant biophysical defects largely account for the clinical
phenotype and identified structural subdomains within the C-terminal
region that regulate ClC-1 channel gating and expression.
2 MATERIALS AND METHODS
2.1 Genetic diagnosis
Written informed consent for DNA storage and use for genetic analy-
sis and research purposes was obtained from all the patients and rela-
tives, as required by the Ethical Committee of the University of Milan
and in accordancewith the Declaration of Helsinki. Genomic DNAwas
extracted from peripheral blood using standard procedures, as previ-
ously described (Ulzi et al., 2012). The 23 coding exons and adjacent
intronic sequences were amplified by PCR (primers are available upon
request), sequenced in an automated sequencer (Applied Biosystem,
USA), and compared with Genbank sequence NM_000083. The mis-
sense mutations identified in patients were not found in 200 Italian
control chromosomes. The new CLCN1 variants were included to the
LeidenOpen Variation Database (http://www.lovd.nl/3.0/home).
2.2 Clinical diagnosis
We investigated seven Italian patients with clinically and genetically
defined MC. All patients were referred to our clinics due to variable
grades of muscle stiffness. Neurological examination was specifically
conducted to search formyotonic signs, such asmuscleweakness, stiff-
ness, and painful myotonia.
2.3 Site-directedmutagenesis and expression ofWT
andmutant hClC-1 channels
Mutations were introduced into the plasmid pcDNA3.1/V5-His TOPO
TA Expression Kit (Invitrogen) containing the full-length wild-type
(WT) hClC-1 cDNA using the Quickchange TM Site-Directed Mutage-
nesis Kit (Stratagene, La Jolla, CA, USA). The complete coding region
of the cDNA was sequenced to exclude polymerase errors. Human
embryonic kidney 293T (HEK293T) cells were transiently transfected
with a mixture of the hClC-1 (5 𝜇g) and CD8 reporter plasmids (1 𝜇g)
using the calcium–phosphate precipitation method (Desaphy et al.,
2013). Cells were examined between 36 and 80 hours after transfec-
tion. Only cells decorated with anti-CD8 antibody-coated microbeads
(DynabeadsM450, Invitrogen) were used for patch-clamp recordings.
2.4 Electrophysiology and data analysis
Standard whole-cell patch-clamp recordings were performed at
room temperature (∼20◦C) using an Axopatch 200B amplifier (Axon
Instruments), as previously described (Desaphy et al., 2013; Imbrici
et al., 2016b; Tricarico et al., 2013). The composition of the extracel-
lular solution was (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, and
5 Hepes, and the pH was adjusted to 7.4 with NaOH. The pipette
solution contained (in mM): 130 CsCl, 2MgCl2, 5 EGTA, and 10Hepes,
and the pH was adjusted to 7.4 with CsOH. In this condition, the
equilibrium potential for chloride ions was about −2.8 mV and cells
were clamped at the holding potential (HP) of 0 mV. Pipettes were
pulled from borosilicate glass and had resistance minor than 2 MΩ,
when filled with the above pipette solutions. More than 80% of series
resistance was compensated using the dedicated Axopatch 200B
circuit to minimize voltage errors, while recordings showing nonnegli-
gible leak current were discarded. Currents were low-pass filtered at
2 kHz and digitized with sampling rates of 50 kHz using the Digidata
1440A AD/DA converter (Axon Instruments). Chloride currents were
recorded ∼5 minutes after achieving the whole-cell configuration, to
allow the pipette solution to diffuse into the cell.
Voltage-dependent channel activity wasmeasured by applying spe-
cific voltage steps from the HP, as described in the Results section and
shown in the figures. We measured the I–V relationship and the over-
all apparent open probability in high-chloride (134 mM) intracellular
solutions to enhance current amplitude. Voltage steps of 400 ms were
applied from −150 to + 120 mV in 10 mV intervals, each followed by
a voltage step at −105 mV during which tail currents were recorded.
Voltage steps were applied every 3 seconds to allow complete recov-
ery of current amplitude at the HP between two pulses.
The instantaneous and steady-state current–voltage relationships
were drawn by measuring instantaneous and steady-state current
densities (pA pF–1) at the beginning (∼1 ms) and end (∼390 ms) of
each voltage step. Overall apparent open probability (Po) for WT and
mutant channels was obtained from normalized peak tail currents
measured during the voltage step at −105 mV reported as a function
of the voltage of the preceding pulses (Desaphy et al., 2013). Thepoints
were fitted with a Boltzmann function:
Po (V) = Pmin +
(
1 − Pmin
)
∕
{
1 + exp
[(
V − V0.5
)
∕k
]}
,
where Pmin is the minimal value of Po, V0.5 is the half-maximal activa-
tion potential, and k is the slope factor.
Open probability for common gating (Po common) was obtained by
using a similar protocol to that for the overall Po (200 ms condition-
ing pulse), except that an extra 400 𝜇s activation pulse to +180 mV
was added before stepping to −105 mV (Imbrici et al., 2015b, 2016b).
This very positive step fully activates the fast gates of the channel and
the tail currents at −105 mV then reflect only slow gating. Apparent
Po total and Po common were calculated from normalized instanta-
neous current amplitudemeasured at the beginning of the tail pulse at
−105 mV. Because overall apparent open probability equals the prod-
uct of its protopore and common components, open probability of the
protopore gates (Po protopore) was then calculated for a given test
voltage by dividing the relevant Po by its corresponding Po common.
The voltage dependence of channel activation was examined by plot-
ting the apparent openprobability as a function ofmembrane potential
and fitting data points with a Boltzmann function.
Data were analyzed off-line by using pClamp 10.3 (Axon Instru-
ments) and SigmaPlot 8.02 (Systat Software GmbH) software.
Results are reported as means ± SEM from n cells, and statistical
analysis was performed using Student's test, with P < 0.05 considered
as significant.
2.5 Homologymodel
To describe the position of the MC ClC-1 mutations in Figure 1, we
used the homology model of the dimeric ClC-1 channel based on
the crystallographic coordinates of the eukaryotic Cl-/H+ exchanger
CmClC (PDB id: 3ORG; Bennetts & Parker, 2013; Feng, Campbell,
Hsiung, &MacKinnon, 2010).
3 RESULTS
3.1 Clinical phenotype ofMC families
Myotonic patients were examined in various Italian clinical centers,
except those carrying the Pro883Thr mutation, who were referred to
theNational referral center for skeletal-muscle channelopathies in the
UK.
Mutation 1: p.Val829Met. A c.2485G>A transition (p.Val829Met)
was identified in a male patient, now 52 years old, with late-onset
myotonia characterized by lower-limb stiffness and myalgia. The CK
levels were normal (300 UI/L). On his last visit, 6 months ago, he
showed autonomous walking, climbing, and descending stairs with-
out support, rising from the chair without specific support. No muscle
deficit was detected on muscle examination. Modest hands myotonia
was evident whereas eyelid myotonia was not detected. The proband
also showedmild hypotrophy in the proximal internal area of the thigh
bilaterally. Control ECG was normal. Molecular testing resulted nega-
tive for myotonic dystrophy type 2 (DM2). The clinical phenotype was
compatible with Thomsen disease. He takes mexiletine 400 mg a day
with a clear benefit on stiffness and cramps; in the past, he took qui-
nine with partial benefit and clonazepam, gabapentin, or pregabalin
that were instead poorly efficacious.
Mutation 2: p.Thr832Ile. The c.2495C>T recessive mutation in
CLCN1, producing the p.Thr832Ile amino acid substitution in ClC-1
protein, was detected in one male patient, in compound heterozygos-
ity with the already known c.180+3A>T mutation. The proband pre-
sented at the age of 20 with lower-limb muscle stiffness and mus-
cle hypertrophy. Neurologic examination revealed mild myotonia with
warm-up, whereas electromyography showed myotonic discharges in
all the investigatedmuscles. The patient is undermexiletine treatment
(600mg a day)with great reduction ofmyotonic episodes. The parents,
both asymptomatic, come from neighboring villages in the province of
Avellino and carry one of the two mutations identified in the proband,
suggesting an autosomal recessive inheritance. The patient is the sec-
ond of two children; the older brother is healthy.
Mutation 3: p.Val851Met.Two related patientswere found to carry
the c.2551G>A (p.Val851Met) mutation in combination with c.86A>C
(p.His29Pro) on the same chromosome. This latter mutation was
F IGURE 1 Structure and alignment of ClC channels. (A) Three-dimensional representation of hClC-1 channel modeled upon the X-ray structure
of an eukaryotic Cl−/H+ exchanger CmClC (Feng et al., 2010) showing the localization of the C-terminal MC mutations. (B) Amino acid alignment
of CLC proteins
previously found in association with p.Tyr257X and p.Ala566Val in
another patient reporting moderate myotonia, permanent limb-girdle
muscle weakness, and scoliosis (Skálová et al., 2013). The proband
is a woman, now 50 years old, who presented with lower-limb mus-
cle weakness, stiffness with difficulty to start movements, and painful
myotonia and warm-up. Symptoms initiated at 16 years old. CK level
was in the standard range. Neurological examination showed muscu-
lar hypertrophywith particular involvement of femoral quadriceps and
gastrocnemius muscles. Myotonia was reported for the lower limbs
and for the hands and facemuscles, andworsenedwith cold. Myotonic
myopathy was also evident on EMG. The clinical phenotype was sug-
gestive of Thomsen disease. At the time of examination, the patient
was taking thiocolchicoside and magnesium pidolate. Concurrent dis-
orders were asthma, hypercholesterolemia, esophagitis, and tachycar-
dia. Therapy includes pantoprazole, diltiazem, olmesartan medoxomil,
flutiform (a combination of fluticasone and formoterol), ebastina,mon-
telukast, and cholecalciferol.
Her father, now 77 years old, noticed weakness, stiffness, myopa-
thy, and painful myotonia at the age of six. In addition to p.Val851Met
and p.His29Pro in cis, he carries the known intronic mutation c.1167-
10T>C (Trip et al., 2008). Myotonic myopathy was also observed in
proband's sister and first-born son of the latter.
Mutation 4: p.Gly859Val. The c.2576G>T substitution
(p.Gly859Val) was identified in a male patient, now 42 years old,
with onset during early infancy, characterized by generalized muscle
stiffness and hypertrophy. Myotonia develops mainly at the begin-
ning of movement after prolonged rest and improves with exercise.
The EMG studies disclosed myotonic discharges in all the examined
muscles, while neurophysiologic test showed a transitory depres-
sion of CMAP. Mexiletine was started at 400 mg/day and was then
incremented to 600 mg/day with a dramatic reduction of myotonia
(Ginanneschi et al., 2017).
Mutation 5: p.Leu861Pro. A c.2582T>C transition (p.Leu861Pro)
was detected in a male patient who showed a very severe form of
myotonia, especially characterized by transitory weakness, sugges-
tive of Becker myotonia. Indeed, the mutation was found in com-
pound heterozygosity with the well-known c.568GG>TC transition
(p.Gly190Ser) (Brugnoni et al., 2013; Desaphy et al., 2013; Shalata
et al., 2010). Proband's father also carries p.Leu861Pro mutation, but
his clinical and neurophysiological examinations resulted negative for
myotonia. The mother, carrying p.Gly190Ser mutation, showed mild
myotonic symptoms nearly limited to lower limbs. She was considered
as affected by Thomsen's myotonia. She always refused any antimy-
otonic treatment. The proband is treated with mexiletine 600 mg/day
since 2005 with good but not dramatic improvement. The 3-Hz repet-
itive nerve stimulation (Lo Monaco et al., 2015) induced a 93% com-
pound muscle action depression before treatment that remained
always above 40% during treatment.
Mutation 6: p.Pro883Thr. The c.2647C>A (p.Pro883Thr) was
found in homozygosity in three unrelated individuals, two of them
were previously reported (Fialho et al., 2007). They were all referred
for genetic testing with a clinical query of MC without any further
details. In one case, the father, who was also reported as symptomatic,
was homozygous for the same mutation. The mother was heterozy-
gous, although she also reported some myotonic symptoms. Unfortu-
nately, no further clinical details are available.
Mutation 7: p.Val947Glu. The c.2840T>A substitution
(p.Val947Glu) was identified in a male patient, now 49 years old,
who showed his first myotonic symptoms at the age of 18. This muta-
tion was found in compound heterozygosity with a novel mutation,
p.Thr533Ile. Neurological examination revealed cold-aggravated
myotonia, mainly in hands, lower-limb muscle stiffness, and general-
izedmuscle hypertrophy.
Figure 1 shows the position of the MC mutations in the human
ClC-1 protein model based upon the X-ray crystal structure of a
eukaryotic CLC transporter from the thermophilic red alga Cyanid-
ioschyzon merolae (CmCLC) (Feng et al., 2010), and the C-terminal
amino acid alignments of ClC-1 from various species and human CLC
proteins.
3.2 Electrophysiological studies of myotonic
mutations in C-terminal region
Chloride currents were recorded in HEK293 cells transfectedwith the
same amount of eitherWTormutant hClC-1 chloride channels, using a
voltage protocol that allows the determination of I–V relationships as
well as the voltage dependence of activation (apparent open probabil-
ity). Chloride currents were recorded using a high-chloride intracellu-
lar solution (134 mM), which allows to clearly distinguish the kinetics
ofWT andmutant channels (Figure 2A).
In these experimental conditions, the p.Val829Met currents were
very similar to WT currents. The I-V relationships for instantaneous
current density were merely superimposed for WT and p.Val829Met,
except for a 35% reduction of steady-state chloride current density
close to the resting membrane potential of muscle cells (−90 mV)
(Figure 2B,C). Conversely, both instantaneous and steady-state cur-
rent amplitudes were greatly reduced through the entire voltage
range for p.Thr832Ile and p.Val947Glu channels, compared with WT
(Figure 2B,C). Different from WT currents, p.Pro883Thr mutant
showed a reduction of the instantaneous current amplitudes and a
peculiar strong outward rectification (Figure 2B,C).
The analysis of the apparent open probability revealed no sig-
nificant difference for p.Val947Glu half-maximum activation voltage
with respect to WT. In contrast, the voltage dependence of activa-
tion of p.Pro883Thr appeared significantly shifted by about 55 mV
toward positive potentials. The voltage dependence of activation
of p.Val829Met and p.Thr832Ile mutants resulted right shifted by
about 20 mV (Figure 2D and Table 1). In order to gain insight into
the pathogenic mechanism behind these mutations, we also analyzed
the effect of the p.Pro883Thr on the protopore and common gat-
ing of the channel. Interestingly, this mutation right shifted the volt-
age dependence for common gating by ∼50 mV compared with WT
(Supporting Information Figure S1).
F IGURE 2 Functional characteristics of myotonic hClC-1 channel
mutants located in the CBS2 domain and C-terminal peptide. (A) Typi-
cal chloride currents recorded in HEK293T cells transfected with WT,
p.Val829Met, p.Thr832Ile, p.Pro883Thr, or p.Val947Glu hClC-1 vari-
ants. Cells were held at 0 mV and 400 ms voltage pulses were applied
from −150 to +120 mV in 10-mV intervals every 3 seconds. For clar-
ity, only current traces obtained every 20 mV are shown. (B) The
instantaneous currents for the indicated channels were measured at
the beginning of test voltage pulses, normalized with respect to cell
capacitance (pA/pF), and reported as a function of voltage. (C) Steady-
state currents were measured at the end of test voltage pulses and
reported as mean current density ± SEM in function of voltage. (D)
The voltage dependence of activation was determined by plotting the
apparent open probability (Po), calculated from tail currentsmeasured
at −105 mV, as a function of test voltage pulses. The relationships
obtained from averaged data were fit with a Boltzmann equation, and
fit parameters are reported in Table 1
3.3 Coexpression experiments of p.Leu861Pro
and p.Gly190Ser
The new recessive mutation, p.Leu861Pro, residing in the CBS2
domain, was associated in compound heterozygosity with the pre-
viously characterized p.Gly190Ser mutation (Desaphy et al., 2013;
Portaro et al., 2015). Chloride currents carried by homomeric
p.Leu861Pro channels were similar to WT currents (Figure 3A). The
current amplitude of instantaneous and steady-state chloride currents
TABLE 1 Biophysical parameters of hClC-1WT andMCmutants
hClC-1
SSC (−90mV)
(pA/pF)
SSC (+60mV)
(pA/pF) V0.5 (mV) K (mV) n cell
WT −81.6± 17 52.1± 10 −68± 0.5 26.8± 0.4 18
p.Val829Met −55.2± 8.6 58.1± 9 −42± 1.5 33.3± 1.4 18
p.Thr832Ile −25.1± 9.6 19.2± 5.6 −48.3± 1.9 42.9± 1.5 5
p.Leu861Pro −68.4± 14.8 54± 14 −69.3± 1 36.4± 0.8 10
p.Pro883Thr −24± 8.5* 59.8± 10 −14.2± 1.3* 26.6± 0.6 7
p.Val947Glu −36.6± 7.8* 24± 5* −77± 0.9 29± 0.8 12
p.Gly190Ser −15.7± 3* 19.2± 5.3* 160± 5.5* 43.7± 1.7 5
p.Leu861Pro+p.Gly190Ser −39.6± 15 60.7± 22 113.8± 3.9* 68.2± 2.1 5
WT+p.Gly859Val −60.2± 13 29.8± 6 −82± 2.1 29.8± 1.4 12
WT+ p.Val851Met −78.4± 30 34± 14 −80.6± 2.2 28.5± 1.6 5
Data are means ± SEM of the indicated number of cells. SSC, steady-state current measured at −90 and +60 mV. V0.5, half-maximal activation potential;
k, slope factor; ∗P< 0.05 or less comparedwithWT.
F IGURE 3 Functional characteristics of p.Leu861Pro, p.Gly190Ser
and coexpressed p.Leu861Pro+ p.Gly190Ser hClC-1 channels. (A–C)
Typical chloride currents recorded in HEK293T cells transfected with
5 𝜇g p.Leu861Pro or p.Gly190Ser mutant alone, or cotransfected
with 5 𝜇g p.Leu861Pro and 5 𝜇g p.Gly190Ser mutants. (D) The
instantaneous currents were measured as in Figure 1B, for
p.Leu861Pro, p.Gly190Ser, and p.Leu861Pro+p.Gly190Ser channels.
(E) Steady-state currents were measured as described in Figure 2C.
(F) The voltage dependence of activations, determined as in Figure 2D,
were fitted with a Boltzmann function. Fit parameters are reported in
Table 1. Dashed line represents theWT currents
for p.Leu861Pro were slightly, albeit not significantly, reduced com-
pared with WT channels, and the voltage dependence of activation of
both channels were superimposed (Figure 3A–C and Table 1). As pre-
viously shown (Desaphy et al., 2013), p.Gly190Ser induced a dramatic
∼260mV shift of the open probability toward positive voltages, result-
ing in zero chloride current within the physiological voltage range of
sarcolemma.
Cotransfection experimentswereperformedwith the sameamount
(5 𝜇g) of p.Leu861Pro and p.Gly190Ser plasmids. The resulting chlo-
ride currents showed properties recapitulating both p.Gly190Ser
and p.Leu861Pro chloride currents: deactivating currents at nega-
tive voltages and tail currents were similar to p.Leu861Pro, whereas
slowly activating outward currents at positive voltages were similar
to p.Gly190Ser (Figure 3A–C). Nevertheless, the instantaneous and
steady-state current densities of coexpressed channels were, at each
voltage, lower than the algebraic sumcurrent densities of p.Leu861Pro
and p.Gly190Ser expressed alone, suggesting a dominant-negative
effect of p.Gly190Ser mutation on p.Leu861Pro. In addition, the
Po was shifted by ∼230 mV toward more positive potentials com-
pared with that of p.Leu861Pro homomeric channels (Figure 3C and
Table 1). Thus, heteromeric p.Leu861Pro+p.Gly190Ser channels were
less likely to be openwithin the physiological voltage range.
3.4 Coexpression experiments ofWT
and p.Gly859Val or p.Val851Met
Two mutations sited in CBS2 domain, p.Gly859Val and p.Val851Met,
were inherited in a dominant manner. These residues are well con-
served among species and among human CLC protein isoforms
(Figure 1). Using MutPred software, p.Val851Met and p.Gly859Val
were, respectively, scored with 0.7 and 0.9 probability to be deleteri-
ous. According to these results, p.Val851Met and p.Gly859Valmutants
did not generate any chloride currents in transfected HEK cells within
the voltage range of−150 to+150mV (Figures 4A and 5A).
In order to test whether these mutations exerted a dominant-
negative effect on wild-type ClC-1 subunits, we coexpressed
p.Val851Met and p.Gly859Val mutants (5 𝜇g) with equal amounts
F IGURE 4 Functional characteristics of p.Gly859Val and coex-
pressed WT+p.Gly859Val hClC-1 channels. (A–B) Typical chloride
currents recorded in HEK293T cells transfected with 5 𝜇g of
p.Gly859Val mutant alone or cotransfected with 5 𝜇g WT and 5 𝜇g
p.Gly859Val. (C) The instantaneous currents were measured as in
Figure 1B, for WT, p.Gly859Val, and WT+p.Gly859Val channels.
(D) Steady-state currents were measured as described in Fig-
ure 2C. (F) The voltage dependence of activation, determined as in
Figure 2C, was fitted with a Boltzmann function. Fit parameters are
reported in Table 1
of WT ClC-1 and examined current density and voltage dependence.
The chloride currents generated in cells transfected with 5 𝜇g of WT
ClC-1 alone were considered for comparison. Both WT+p.Val851Met
(Figure 5) andWT+p.Gly859Val (Figures 4B and 5B) channels showed
gating properties similar to WT, with both inwardly and outwardly
rectifying currents. The instantaneous and steady-state currents
generated by either coexpressed channels or homomeric WT were
superimposed, suggesting that the p.Val851Met and p.Gly859Val pore
mutant subunits did not exert ameasureable dominant-negative effect
onWT in coexpression experiments (Figures 4C–E and 5C–E).
4 DISCUSSION
In this study, we report a thorough characterization of newly identified
myotonicmutations located in theC-terminal of theClC-1 channel and
associated with different grades of myotonic symptoms that provide
F IGURE 5 Functional characteristics of p.Val851Met and coex-
pressed WT+p.Val851Met hClC-1 channels. (A–B) Typical chlo-
ride currents recorded in HEK293T cells transfected with 5 𝜇g
p.Val851Met mutant alone or cotransfected with 5 𝜇g WT and 5 𝜇g
p.Val851Met mutant. (C) The instantaneous currents were measured
as in Figure 1B, forWT, p.Val851Met, andWT+p.Val851Met channels.
(D) Steady-state currents were measured as described in Figure 2C.
(F) The voltage dependence of activations, determined as in Figure 2D,
were fitted with a Boltzmann function. Fit parameters are reported in
Table 1
relevant information about the contribution of the C-terminal domain
to ClC-1 activity.
4.1 Genotype–phenotype correlation
The clinical examination of patients carrying p.Val851Met and
p.Gly859Val suggested a Thomsen's phenotype associated with
moderate myotonia and mild muscle stiffness, which was consistent
with the functional analysis of mutant channels. When expressed
in HEK cells, these mutants did not produce any chloride currents,
confirming their pathogenicity in producing myotonia. Despite such a
drastic effect, coexpression experiments performed to reproduce the
heterozygous condition of the affected patients demonstrated that
p.Val851Met and p.Gly859Val mutations did not exert any dominant-
negative effect onWTClC-1 subunits, thereby ensuring at least half of
the sarcolemma chloride conductance. This suggests that WT subunit
might temper the severe biophysical defect of individual mutant
channels, thus explaining the mild myotonic phenotype of affected
carriers (Table 2).
TABLE 2 Genotype–phenotype correlation
Genotype Inheritance Clinical phenotype Therapy Functional defect
p.Val829Met AD Mild withmuscle stiffness and pain Mexiletine 400mg/day Small voltage-dependent
shift
p.Thr832Ile AR (c.180+3A>T) Mild withmuscle stiffness,
hypertrophy andwarm-up
Mexiletine 600mg/day Small voltage-dependent
shift
p.Val851Met AD (p.His29Pro in cis) Mild withmuscle stiffness and pain,
hypertrophy, weakness and
warm-up
Thio-colchicoside,
magnesium pidolate
Nonfunctional channels w/o
dominant-negative effect
p.Gly859Val AD Mild withmuscle stiffness,
hypertrophy, weakness and
warm-up
Mexiletine 600mg/day Nonfunctional channels w/o
dominant-negative effect
p.Leu861Pro AR (p.Gly190Ser) Severe withmuscle weakness Mexiletine 600mg/day Similar toWT but
dominant-negative effect
with p.Gly190Ser
p.Pro883Thr Homozygous n.a. n.a. Large voltage-dependent
shift
p.Val947Glu AR (p.Thr533Ile) Mild withmuscle stiffness and
hypertrophy
n.a. great reduction of chloride
current
n.a., information not available.
The p.Val947Glu mutation was identified in a male patient who
showed a mild form of MC. Functional characterization revealed that
p.Val947Glu mutant channels showed a 60% reduction of chloride
currents, although the voltage dependence resulted similar toWT. The
mutation was inherited in compound heterozygosity with p.Thr533Ile,
a mutation never characterized before. p.Thr533Ile is located at the
helix O of the human ClC-1 and has a medium likelihood of being
deleterious as predicted by MutPred Software analysis (score 0.54).
Othermutations near this residue are associatedwith amyotonic phe-
notype, such as p.Ala531Val (Desaphy et al., 2013; Lee et al., 2013),
p.Ala535Asp, and p.Val536Leu (Brugnoni et al., 2013), thus suggest-
ing the importance of this region for proper ClC-1 function and sup-
porting the probable pathogenicity of p.Thr533Ile. The coexistence of
p.Val947Glu and p.Thr533Ile in the proband is therefore likely respon-
sible for themildmyotonic phenotype.
Two othermutations in theCBS2 domainwere associatedwithmild
myotonic symptoms, p.Val829Met and p.Thr832Ile. When expressed
in HEK293T cells, p.Val829Met and p.Thr832Ile did not change chlo-
ride current density but induced a slight shift of voltage dependence
toward positive potential. Such an effect may be sufficient to recapitu-
late themild clinical phenotype found in the patients.
The p.Leu861Pro variant located in the CBS2 domain was associ-
ated with a severe phenotype and was scored with a 0.8 probability to
be deleterious (mutPred). The residue is conserved in ClC-1 from dif-
ferent species, though the sequence stream where it is located varies
among human CLC protein paralogs. The functional characterization
of p.Leu861Pro mutant revealed that current amplitude and voltage
dependence were very similar to those of WT protein, thus question-
ing its pathogenicity. Indeed, the proband's father carrying this muta-
tion in heterozygosity was asymptomatic. Besides p.Leu861Pro, the
proband also carries the well-known p.Gly190Ser mutation (Desaphy
et al., 2013; Portaro et al., 2015). Coexpression experiments with
p.Leu861Pro and p.Gly190Ser produced chloride currents smaller
than those of p.Leu861Pro alone, suggesting a dominant-negative
effect of p.Gly190Ser on the p.Leu861Pro subunit. It is thus likely
that the severity of myotonia in the proband may stem from such a
specific dominant-negative effect exerted by the p.Gly190Ser sub-
unit on the p.Leu861Pro subunit. Interestingly, we previously did not
observe a dominant-negative effect of p.Gly190Ser on theWT subunit
(Portaro et al., 2015), in agreement with the mild myotonic phenotype
observed in the proband's mother carrying only p.Gly190Ser. Overall,
these results suggest that p.Leu861Promight act as a diseasemodifier
able to worsen the phenotype caused by the coexisting p.Gly190Ser
poremutation without being pathogenic by itself.
4.2 ClC-1 structure–function relationship
The role of the C-terminal domains of CLC channels was investigated
through the study of point mutations identified in this region associ-
ated with several inheritable diseases (Koch et al., 1992; Kornak et al.,
2001; Simon et al., 1997). Deletions, truncations, or missense muta-
tions in the C-tail resulted in poor expression, altered gating, or non-
functional channels, demonstrating its physiological relevance (Ma,
Rychkov, Hughes, & Bretag, 2009).
In hClC-1, the CBS2 domain encompasses residues 820 to 871
(Estévez et al., 2004; Hebeisen et al., 2004) and has been predicted
to play a role in channel gating. Indeed, structural studies on ClC-
1 suggested that the long intracellular C-terminal portion is folded
in such a manner that the CBS2 domain may directly interact with
the 𝛼-helix R containing Tyr578 residue, which participates directly
in Cl− coordination during transport (Feng et al., 2010; Imbrici et al.,
2015b). Moreover, several mutations occurring in CBS2 have been
shown to cause changes in channel voltage dependence, and a mutant
with a particularly strong effect, p.His835Arg, displayed a dominant-
negative effect onWT in coexpression studies, suggesting an alteration
of the common gate (Estévez et al., 2004). Consistent with a role of
CBS2 in ClC-1 gating, both p.Val829Met and p.Thr832Ile mutations,
falling within CBS2, showed a positive shift of channel voltage depen-
dence. Two other neighboringmutations located in CBS2 andwell con-
served among CLC proteins, p.Val851Met and p.Gly859Val, failed to
F IGURE 6 Clustering of MCmutations. Schematic drawing showing
clusters of ClC-1 mutations within CBS2 and C-terminal peptide sub-
domains that share the same functional defect
generate chloride current, suggesting either nonfunctional channels or
poor expression due to a defect in protein translocation to the mem-
brane. Interestingly, p.Gly859Asp is also associated with a lack of cur-
rent, suggesting presumably a similar disruption of the CBS domain
structure (Bennetts et al., 2005).
In contrast, p.Leu861Pro mutation did not alter ClC-1 function,
showingabehavior similar toWT.Wecannot exclude that themutation
may affect the channel regulation by intracellular metabolites. Indeed,
previous studies have shown that theC-terminal cytoplasmic domain is
sensitive to a range of modulators (Pedersen, Riisager, de Paoli, Chen,
& Nielsen, 2016), including nucleotides, such as ATP and NAD+, or
regulatory proteins such as PKC (Bennetts et al., 2005, 2012; Hsiao
et al., 2010; Tseng et al., 2011). The mutation p.Leu861Pro falls within
the putative ATP binding site in CBS2, including residues Glu865 and
His847 and Leu848 (Bennetts et al., 2012; Tseng et al., 2011).
Among mammalian CLC proteins, the skeletal-muscle chloride
channel ClC-1 has the longest C-terminal peptide after the second
CBS domain (Park & MacKinnon, 2018). Our results show that the
C-peptide is important for ClC-1 function and expression. Mutation
of Pro883 to Thr induced a dramatic reduction of chloride current
amplitude due to a positive shift of voltage dependence of common
gating. Interestingly, a similar effect has been described for the
nearby p.Ala885Pro mutation identified in the myotonic goat, which
generated chloride currents with reduced macroscopic amplitude
and altered gating (Beck et al., 1996; Macias et al., 2007). Through
functional, biochemical, and NMR spectroscopy studies, these authors
demonstrated that the C-terminal region encompasses a conserved
segment that folds with a secondary structure containing a short type
II poly-proline helix. The flexibility of the last part of the conserved
segment appeared critical for channel function. The myotonia-causing
mutation p.Ala885Pro extended the poly-proline helix, likely causing a
reduction of flexibility of this region.We can thus hypothesize that Pro
to Thr mutation in 883 position may also disturb C-terminal flexibility,
thereby altering voltage dependence.
Besides, C-peptide also plays an important role in ClC-1 trafficking
to the sarcolemma. Previous studies suggested that mutations iden-
tified in the most distal part of this region (e.g., p.Arg894stop and
p.Pro932Leu) reduced plasma membrane expression (Macias et al.,
2007). The results obtained with p.Val947Glu fully agreed with this
hypothesis, since this mutation reduced chloride current amplitude
without altering the voltage dependence of open probability.
Altogether, the functional characterization of MC mutations
allowed us to define the specific role of CBS2 subdomains: mutations
between 829 and 835 residues may induce an alteration of voltage
dependence, mutations between 851 and 859 residues may produce
nonfunctional channels, whereas mutations on 861 residue display no
apparent change in ClC-1 (Figure 6). The functional analysis of a higher
number of mutations is warranted to confirm this structure–function
correlation.
In conclusion, the present study expands the spectrum of CLCN1
mutations responsible for MC and clarifies the role of the C-terminal
region in ClC-1 expression and gating. The comprehension of the
molecular mechanisms underlying MC together with improved under-
standing of the structure–function relationship of ClC-1 protein could
help the discovery of new drugs targeting specific mutant channels’
defects, allowing the development of a personalized treatment forMC
patients (Imbrici et al., 2016a).
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